MONTREAL and CHARLOTTE, N.C., June 2, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer,

MONTREAL and CHARLOTTE, N.C. , May 27, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Milestone's Compensation Committee granted three new

MONTREAL and CHARLOTTE, N.C. , May 17, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto , President and Chief Executive

-       RAPID topline data readout remains on track for mid-second half 2022 -       Results from NODE-302 study highlights etripamil safety and reduced need for ED interventions MONTREAL and CHARLOTTE, N.C. , May 12, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc.

- Patients successfully self-managed PSVT episodes with etripamil which reduced need for ED intervention - - As in other studies, etripamil was well tolerated by patients - - Data to be featured during late breaking session at Heart Rhythm 2022 - MONTREAL and CHARLOTTE, N.C.

MONTREAL and CHARLOTTE, N.C. , April 15, 2022 /PRNewswire/ --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Milestone's Compensation Committee granted one new

Cardiac Electrophysiology Key Opinion Leaders to include Bruce Stambler , MD and Sean Pokorney , MD Conference call and webcast on Thursday, April 21, 2022 at 1:00 p.m. ET MONTREAL and CHARLOTTE, N.C. , April 14, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc.  (Nasdaq: MIST), a

-       RAPID topline data readout expected mid-second half 2022 MONTREAL and CHARLOTTE, N.C., March 24, 2022 /PRNewswire/ --  Milestone Pharmaceuticals Inc.  (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today

MONTREAL and CHARLOTTE, N.C., March 1, 2022 /PRNewswire/ --  Milestone Pharmaceuticals Inc.  (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of management will present at the following

MONTREAL and CHARLOTTE, N.C., Feb. 16, 2022 /PRNewswire/ --   Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of David Bharucha , M.D., Ph.D., as Chief